ARA-290

ARA-290 (Cibinetide) is a synthetic 11-amino acid peptide derived from the structure of erythropoietin (EPO) that activates the innate repair receptor (IRR, a heteromer of EPO receptor and CD131) without stimulating erythropoiesis. This tissue-protective mechanism is distinct from EPO's hematopoietic effects. Research demonstrates ARA-290 reduces neuropathic pain, promotes tissue repair, decreases inflammation, and protects against ischemic injury in multiple organ systems. Clinical trials have evaluated the peptide for diabetic neuropathy, sarcoidosis, and critical limb ischemia with evidence of improved symptoms and tissue healing. The peptide does not increase red blood cell production, eliminating concerns about polycythemia and thrombotic events associated with EPO therapy. Studies show beneficial effects on small fiber neuropathy, wound healing, and metabolic parameters. ARA-290 may help restore corneal nerve fiber density and improve sensory function. The tissue-protective EPO signaling pathway represents a novel therapeutic target for conditions involving inflammation and tissue damage without the risks of erythropoiesis stimulation.

Evidence is limited to small, exploratory, company-sponsored trials; no large phase 3 or regulatory approval exists. Benefits were modest and some endpoints (e.g., depression scores) showed no change. The product is not marketed for any approved indication.

ARA-290 is an 11-amino-acid peptide derived from the EPO structure that binds the innate repair receptor (EPOR/CD131 heteromer) without activating hematopoietic signaling. Studied routes include intravenous (2 mg 3x/week in the sarcoidosis trial) and subcutaneous (4 mg daily in the T2D trial). It does not stimulate red blood cell production. No pharmacokinetic half-life data were reported in the indexed trials.